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Samer Salah1*, Akram Al-Ibraheem2, Amal Daboor3 and Maysa Al-Hussaini3Abstract
Background: Synovial sarcoma presenting in the mediastinum is exceedingly rare. Furthermore, data addressing
optimal therapy is limited. Herein we present a case where an attempt to downsize the tumor to a resectable state
with chemotherapy was employed.
Case presentation: A 32 year female presented with massive pericardial effusion and unresectable huge
mediastinal mass. Computed axial tomography scan - guided biopsy with adjunctive immunostains and molecular
studies confirmed a diagnosis of synovial sarcoma. Following three cycles of combination Ifosfamide and
doxorubicin chemotherapy, no response was demonstrated. The patient refused further therapy and had
progression of her disease 4 months following the last cycle.
Conclusion: Synovial sarcoma presenting with unresectable mediastinal mass carry a poor prognosis. Up to the
best of our knowledge there are only four previous reports where primary chemotherapy was employed,
unfortunately; none of these cases had subsequent complete surgical resection. Identification of the best treatment
strategy for patients with unresectable disease is warranted. Our case can be of benefit to medical oncologists and
thoracic surgeons who might be faced with this unique and exceedingly rare clinical scenario.
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Soft tissue sarcomas (STS) are rare malignant tumors
that comprise less than 1% of malignant neoplasms. In
the thorax, where the majority of malignant tumors are
carcinomas, the proportion of STS is even much less;
probably less than 0.01% of all malignant thoracic neo-
plasms [1]. A population based study demonstrated that
17% of new cases of STS including variety of histologies
arise in the thorax, accounting for an approximate inci-
dence of primary thoracic STS of 6 per million popula-
tions [2]. These tumors may arise in variety of locations
including lung, mediastinum, heart, and pleura.
The mediastinum as a primary site of occurrence of
synovial sarcoma is exceedingly rare. Although complete
resection had been the only therapy associated with long* Correspondence: ssalah@khcc.jo
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reproduction in any medium, provided the orterm survival, uncertainty exists regarding the best thera-
peutic strategy for patients with unresectable disease.
External beam radiotherapy (EBRT) is the most commonly
employed primary therapy when the mass is unresectable
[3,4]. Chemotherapy as a primary therapy, on the other
hand, is only rarely reported [5]; there are only four previ-
ous reports where chemotherapy was employed as the
primary therapy amongst 16 reported cases of unresectable
primary mediastinal synovial sarcoma (Table 1). In this
case report, we present the outcome following combin-
ation chemotherapy that was delivered as a primary
therapy in an attempt to downsize the tumor to achieve
resectability, and review the available literature in an
attempt to shed light on the available therapeutic options
for this kind of clinical presentation.
Case presentation
A 35 year old female presented with bilateral lower limb
swelling and exertional shortness of breath that had devel-
oped over few weeks. She was found to have pericardialtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Primary mediastinal synovial sarcoma patients presenting with unresectable/ advanced disease
Author Age/ Gender Presentation Histologic subtype Treatment Outcome
de Zwaan C, et al. Neth Heart J.
2007;15(6):226–8.
19 / M S.O.B, congested neck veins,
edema, cardiac tamponade
M Patient refused therapy DWD at 3 months.
Korula A, et al. Singapore Med J.
2009 Jan;50(1):e26-8.
49 / M S.O.B, chest pain, Pericardial
effusion
NA Supportive care only. Patient refused CTX NA
Suster S, et al. Am J Surg Pathol.
2005 May;29(5):569–78.
13 / M Weakness, S.O.B, right pleural
effusion
M EBRT only DWD at 6 months after developing
liver metastases.
23 / F Weakness, chest pain B Partial excision followed by EBRT NA
48 / M Chest pain M EBRT only NA
54 / F Left shoulder pain B Partial excision followed by EBRT Local progression and epidural
metastasis at one year. DWD.
83 / M S.O.B, pleural effusion M EBRT only NA
Arafah M, et al. Indian J Pathol
Microbiol. 2011 Apr-Jun;54(2):384–7.
30 / M S.O.B, cough, weight loss M Palliative CTX (Ifosfamide+Doxorubicin) Regression of mediastinal mass
after 3 cycles. AWD at 6 months
Hung JJ, et al. Ann Thorac Surg.
2008 Jun;85(6):2120–2.
24 / M Chest pain, S.O.B, back pain,
cough, fevers
M Partial excision followed by EBRT PD five weeks after EBRT (local+lung
metastases). PD with bone metastases
following treatment with Ifosfamide
and epirubicin. DWD 6 months
after diagnosis.
Paquette M, et al. J Thorac Oncol.
2010 Jun;5(6):898–906.
NA NA NA EBRT only PR following EBRT. Local progression
at 32 months.
DWD at 38 months.
NA NA NA CTX (Ifosfamide+Doxorubicin) PD during CTX. DWD at 5 months
Trupiano JK, et al. Ann Thorac Surg.
2002 Feb;73(2):628–30.
30 / F Incidental on imaging B Partial resection and combination CTX DWD at 10 months
Nakagawa Y, et al. Nihon Kokyuki
Gakkai Zasshi. 2010 Oct;48(10):734–8.
65 / M Cough with bloody sputum NA CTX, EBRT, and hyperthermia PD following CTX, EBRT, and
hyperthermia. DWD at 20 months.
Lee HJ, et al. J Lung Cancer 2008;
7(1):29-33
44 / M Cough, SOB, chest pain M Partial resection following PR to neoadjuvant
Adriamycin+ Dacarbazine
Adjuvant EBRT (59.4 Gy in 33 fractions).
Developed bilateral lung metastases
three months after finishing EBRT.
Kaira K, et al. J Comput Assist
Tomogr. 2008 Mar-Apr;32(2):238-41
64 / F Back pain, dysphagia NA EBRT, CTX upon PD (Ifosfamide+Doxorubicin),
re-irradiation and hyperthermia
Symptomatic improvement after EBRT,
response to CTX, DWD at 24 months
58 / M Right sided back pain NA EBRT and hyperthermia, CTX
(Ifosfamide+Doxorubicin) upon PD,
second line CTX (Gemcitabine + Docetaxel),
third line carboplatin
Initial response after EBRT, hyperthermia, and
first line CTX, DWD at 19 months
Current case 32 / F S.O.B, lower limb edema,
pericardial effusion
M CTX (Ifosfamide +Doxorubicin) PD after CTX, refused further therapy.
AWD at 11 months
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was discharged two days later on non-steroidal anti-
inflammatory medication after showing subjective im-
provement. Two weeks later, she had recurrence of her
symptoms due to recurrent pericardial effusion with signs
of impending tamponade that was managed with a pericar-
dial window. A computed axial tomography (CT) scan of
the thorax demonstrated a huge mediastinal mass, for
which a CT guided biopsy was carried out. The patient was
referred to us later for further evaluation. On presentation
she was asymptomatic and her physical examination
disclosed mild bilateral pitting edema, but was otherwise
noncontributory. A review of her CT scan showed a huge
mass in the anterior mediastinum and no evidence of dis-
tant metastases. Review of her pathology specimen showed
proliferation of spindle cells with oval normochromatic
nuclei, scattered mitotic figures and no evidence of ne-
crosis. Prominent thin- walled blood vessels were seen
with branching embarking a hemangiopericytoma-like
vascular pattern (Figure 1A). No epithelial components
could be appreciated. A panel of immunostains was done.
The tumor cells were positive for epithelial membrane
antigen (EMA), and focally positive for pan-cytokeratin
(MNF) (Figure 1B) as well as for BCL-2 (Figure 1C) and
FLI-1 (Figure 1D). They were negative for CD99, S100
protein, CD34, CD31, DOG-1, C-kit, CD20 and CD3Figure 1 Pathologic examination of the mediastinal mass biopsy. (A)
hemangiopericytomatous vessels (H&E X40). (B) Scattered positivity in tumo
positivity for Bcl-2 is appreciated (X40). (D) Fli-1 nuclear stain is seen in this
cells hybridized with LSI SS18 (18q11.2) Dual Color, Break Apart Rearrangem
one green signal pattern indicative of a rearrangement of one copy of the
of synovial sarcoma.immunostains, which essentially excluded other sarcomas,
germ cell tumors and lymphomas. The morphological and
immunostains supported the diagnosis of synovial sar-
coma, monophasic variant, which was confirmed with
Fluorescence in situ hybridization (FISH) testing for ss18
gene rearrangement (Figure 1E). A Positron emission tom-
ography/ CT (PET/ CT) scan was carried out and dem-
onstrated the huge hyper-metabolic mass, with a maximum
standardized uptake value (SUVmax) of 6, in the anter-
ior mediastinum and ruled out distant metastatic sites
(Figure 2).
The mass was unresectable according to the thoracic
surgeons’ assessment because it was invading the peri-
cardium and engulfing the major vessels. We elected
to proceed with combination chemotherapy in an at-
tempt to downsize her tumor for possible subsequent
resection. The option of EBRT was discussed, however;
given the huge size of her mediastinal mass, a suffi-
cient and definitive dose of radiation would not be feas-
ible without severe toxicity. She received three cycles of
Ifosfamide 2g/m2 every 12 hours D1-D3, Doxorubicin
75 mg/m2, Mesna and Granulocyte-colony stimulating
factor (GCSF) starting 24 hours following completion
of chemotherapy and continued until neutrophil recov-
ery. She had recurrent neutropenic fever following the
first two cycles in addition to severe thrombocytopeniaThe tumor shows proliferation of oval cells separated by
r cells for pancytokeratin (MNF) can be seen (X20). (C) Cytoplasmic
case (X40). CD99 was completely negative (not shown). (E) Abnormal
ent Probe. The cells in this image show one fusion, one orange, and
SS18 gene region. These findings were consistent with the diagnosis
Figure 2 PET/CT performed for characterization and staging of the tumor. Axial contrast enhanced CT scan (A) showed heterogeneously
enhanced anterior mediastinal soft tissue mass (circle) engulfing the major vessels , axial PET (B) and PET/CT (C) revealed a huge hyper-metabolic
mass (circle) in the anterior mediastinum which demonstrated heterogeneous increased FDG metabolic activity with a maximum standardized
uptake value (SUVmax) of 6. Maximum intensity projection (MIP) image (D) also illustrated this mass (circle) in the coronal dimension. Remainder
of the PET/CT exam was negative for any distant hyper-metabolic lesions.
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25% dose reduction of both agents in the third cycle.
Her chest CT scan following the third cycle showed
slight increase in tumor size. The patient refused fur-
ther therapy and was referred to palliative care. Three
months later, she started to suffer from progressive short-
ness of breath and chest discomfort secondary to mass
effect, A CT scan of her chest and abdomen showed pro-
gression of the size of the mass without distant metasta-
sis. The patient is still alive with her disease 11 months
after diagnosis.
Discussion
Primary thoracic sarcomas are rare group of neoplasms
that may arise in mediastinum, heart, lung, and pleura, and
includes a wide variety of possible histologic subtypes. Al-
though angiosarcoma, leiomyosarcoma, sarcomatoid meso-
thelioma, and rhabdomyosarcoma are the most commonly
encountered histologies, other subtypes including synovial
sarcoma, fibrosarcoma, malignant fibrous histiocytoma,
chondrosarcoma, and primitive neuroectodermal tumors
may arise in these locations. Apart from rhabdomyosar-
coma which has a bimodal occurrence (children, fifth to
seventh decades), almost all of these tumors affect middle
aged and elderly patients, and there occurrence in children
is exceedingly rare [6].Morphologically, synovial sarcoma can show several
growth patterns and is basically divided into monophasic
and biphasic subtypes. The better recognized variant is the
biphasic synovial sarcoma which consists of proliferation
of bland looking spindle-shaped cells in a collagenous
background and hemangiopericytomatous vascular growth
pattern, along with evidence of epithelial differentiation
ranging from well-formed gland-like structure to aggre-
gates of cudoidal cells. Monophasic tumors on the other
hand can show either spindle cells only or occasionally
might consist of epithelial component only [7]. A poorly
differentiated variant of synovial sarcoma is also recognized
[8]. Immunostains has been invaluable in supporting the
diagnosis of synovial sarcoma, especially with limited bi-
opsy material as in our case, when the diagnostic features
are not well represented, or in the poorly differentiated
variant. The expression of epithelial markers in the gland-
like component and more importantly in the spindle cell
component supports the diagnosis. Among all epithelial
markers, EMA is the most commonly positive marker [8].
Pan-cytokeratin, cytokeratin 7, and 19 can also be positive
in the epithelial-like component as well as the spindle cell
component [9]. In addition; positivity for bcl-2 can be seen
in some cases [10]. Recently; TLE1 has been described as a
diagnostic marker for synovial sarcoma which is claimed to
be more sensitive and specific than others [11].
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sarcomas can arise in any site including head and neck, ab-
dominal wall, lungs, and genitourinary tract. Nevertheless,
the mediastinum as a primary site of occurrence is rare
with less than 40 reported cases in literature.
Because the mediastinum is a host for a variety of pri-
mary and secondary neoplasms, differentiating synovial
sarcomas from variety of other, more commonly encoun-
tered diagnoses such as lymphoma, mesothelioma, thym-
oma, metastatic carcinomas, as well as other sarcoma
subtypes is of paramount importance. Careful assessment
of biopsy specimen, with adjunctive imunostains is neces-
sary for appropriate diagnosis. The availability of molecular
genetic identification (FISH or polymerase chain reaction)
of the t(X;18) has improved diagnostic specificity for syn-
ovial sarcomas as this translocation is found in over 90% of
cases [13]. Testing for this translocation is important to
confirm a suspected diagnosis of synovial sarcoma when it
arises in a rare location.
Following establishment of diagnosis of a mediastinal or
cardiac sarcoma, accurate staging to identify the extent of
disease and to rule out distant metastases is an important
and essential step for subsequent management.
Apart from rhabdomyosarcoma and primitive neuro-
ectodermal tumors, which require histology-specific
chemotherapy regimens as integral part of treatment, man-
agement of other histologic subtypes, regardless of age and
location, share same general principles. Surgical resection
is the cornerstone of therapy of thoracic STS including
those arising in the mediastinum if the mass is resectable;
in fact, the ability to completely resect the mass is the most
important factor associated with long term survival [3].
Although there are no randomized phase III studies
to define the most effective modality, patients with
unresectable sarcomas are usually treated with systemic
chemotherapy and/ or EBRT [14,15]. Because an adequate
response to EBRT and chemotherapy may convert an ini-
tially unresectable tumor to one that can be resected and
potentially cured, the choice of particular type of chemo-
therapy regimen or of radiotherapy is usually guided by
the sarcoma histologic subtype, given the recognized
wide variability of response of different STS subtypes
to chemotherapy regimens and radiotherapy. Combination
chemotherapy in this setting is preferable over single
agents because of the higher probability of achieving an
adequate response.
For patients presenting with unresectable mediastinal
synovial sarcomas, very limited data exists regarding the
optimal therapy that can effectively downsize the tumor
to resectable state. A review of literature identified only
34 cases of primary synovial sarcoma of the mediastinum,
16 of them presented as unresectable disease (Table 1).
The most commonly employed therapeutic modality for
patients with unresectable disease is EBRT. There areonly four reports where chemotherapy had been the pri-
mary therapy, It is worth noting that amongst those pa-
tients who presented with unresectable disease, none had
subsequent complete surgical resection. Most cases had
progressed locally and at distant sites shortly following
completion of radiotherapy and chemotherapy and died
within two years of diagnosis, with no reported long term
survivals.
Unlike patients with unresectable disease, patients
whose’ disease can be completely resected had a better
chance for long term survival; Gerry Van der Mieren et al.
[16], reported a patient who survived more for 14 years
with a strategy of repeated surgical resection.
In patients with resectable mediastinal disease, the
prognosis seems to be worse than patients with resect-
able extremity synovial sarcomas, as most of the reported
cases of mediastinal synovial sarcomas had local or dis-
tant recurrences following complete surgical resection
[17,18]. This high rate of local and distant failure
suggests that adjuvant multimodality therapy following
resection might be warranted.
Conclusions
Synovial sarcoma arising in the mediastinum is a rare
disease entity. Complete surgical resection is the only
known factor associated with possible long term sur-
vival. When arising as unresectable mediastinal mass,
the prognosis is extremely poor. Reports of effective
downsizing strategies and studies addressing the best
integration of chemotherapy and radiotherapy in patients
with unresectable mediastinal disease are warranted. Our
case can be of benefit to medical oncologists and thoracic
surgeons who might be faced with this unique and exceed-
ingly rare clinical scenario.
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